ACADIA Pharmaceuticals Builds Growth Momentum as DAYBUE and NUPLAZID Sales Rise

Key Points

• ACADIA reported Q2 2026 revenue of approximately $308 million and net income of $31.5 million.
• Management increased 2026 revenue guidance to $1.24 billion–$1.30 billion.
• DAYBUE generated approximately $125 million in second-quarter net product sales.
• NUPLAZID generated approximately $183 million in second-quarter net product sales.
• ACAD shares gained roughly 11.9% in the month through August 28.
• Continued prescription growth, payer access, and pipeline progress will determine whether the company can sustain its current momentum.

 ACADIA Pharmaceuticals (NASDAQ: ACAD) is showing stronger commercial and financial momentum in 2026, supported by rising sales of DAYBUE and NUPLAZID, improved profitability, and a higher full-year revenue outlook. The company reported second-quarter revenue of nearly $308 million and raised its 2026 total-revenue guidance to $1.24 billion to $1.30 billion.

Growing DAYBUE Sales Strengthen ACADIA’s Rare-Disease Franchise

DAYBUE is ACADIA’s treatment for Rett syndrome, a rare genetic neurological disorder. The product generated approximately $125 million in net sales during the second quarter of 2026, making it an increasingly important contributor to company growth.

The continued adoption of DAYBUE gives ACADIA exposure to the rare-disease market, where successful therapies can benefit from focused patient populations and specialized treatment networks. Future growth will depend on identifying untreated eligible patients, maintaining coverage and reimbursement, supporting treatment persistence, and expanding awareness among healthcare providers and families.

NUPLAZID Remains a Major Revenue Base for ACADIA

NUPLAZID generated approximately $183 million in Q2 2026 net product sales, maintaining its role as ACADIA’s largest commercial product. The medicine is used to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

NUPLAZID’s established revenue base provides cash flow and commercial infrastructure that supports ACADIA’s broader growth strategy. However, the company must continue to sustain demand, preserve payer access, manage competition, and limit the impact of any changes in prescribing patterns or healthcare reimbursement.

Higher Revenue Outlook Reflects Stronger Commercial Execution

Following second-quarter results, ACADIA raised its 2026 total-revenue guidance to a range of $1.24 billion to $1.30 billion. The upgraded outlook reflects management’s increased confidence in the performance of DAYBUE and NUPLAZID.

ACADIA reported Q2 revenue of $307.96 million and net income of $31.5 million, showing that its commercial growth is also supporting profitability.

The company’s ability to maintain this momentum will depend on continued product uptake, efficient sales and marketing investment, stable gross margins, and disciplined operating spending.

ACAD Stock Performance Reflects Improving Investor Sentiment

ACAD shares gained approximately 11.9% in the month ending August 28, reflecting stronger investor interest following the company’s earnings update and raised outlook. The stock reached an intramonth high of $30.96 on August 19 before consolidating near $29 by the end of the period.

Share-price performance can remain volatile, particularly in the biotechnology sector. Investors will continue to evaluate whether improving commercial results are sustainable and whether ACADIA can add new growth drivers beyond its current product portfolio.

What ACADIA Investors Should Watch Next

The next major indicators for ACAD investors are DAYBUE patient starts and persistence, NUPLAZID prescription trends, progress toward the company’s updated 2026 revenue target, operating-margin performance, and ongoing profitability.

Pipeline development also remains important. Progress with remlifanserin and other programs could broaden ACADIA’s long-term growth profile, while delays, weaker product demand, reimbursement challenges, or increased competition could affect future results. ACADIA enters the second half of 2026 with stronger commercial momentum, but sustained execution will determine whether that growth translates into durable shareholder value.